Delta opioid receptors have a built-in mechanism for pain relief and can be precisely targeted with drug-delivering nanoparticles—making them a promising target for treating chronic inflammatory pain with fewer side effects, according to a new study from an international team of researchers. The study is published in Proceedings of the National Academy of Sciences. Full story.
Share this post
Share on facebook
Share on twitter
Share on linkedin
Share on print
Share on email